Gene Therapies Hold Promise for Neuromuscular and Other Rare Diseases
Challenges remain, however, to therapy development for a limited patient population.
Source: pharmacytimes.com
Comp Eff News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Comp Eff. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Comp Eff Today - Breaking & Trending Today
Digital Musculoskeletal Program Is Associated With Decreased Joint Replacement Rates
Adults with osteoarthritis who took part in a digital musculoskeletal program had lower rates of knee and hip arthroplasty at 12 months vs those using traditional care.
Source: ajmc.com
Frontiers | The Need for Parental Support for Migrant Parents in Transition Into Sweden: A Perspective
Migration is a stressful experience and research shows that newly arrived migrants in Sweden suffer from different challenges and struggle to relate to parenting in a new culture that is different from their own. The Swedish Child Health Services (CHS) focuses on promoting health among children, as well as supporting parents in parenting. Although this is a goal, migrant parents participate at lower rates in parental support groups. This paper aims to discuss how the Swedish CHS can support these families and address the need for improvement in the parental support offered to migrant parents d...
Source: frontiersin.org
Daiichi Sankyo UK, Limited: ENHERTU - (TRASTUZUMAB DERUXTECAN) NOW AVAILABLE VIA THE CANCER DRUGS FUND FOR THE TREATMENT OF HER2 POSITIVE METASTATIC BREAST CANCER
Daiichi Sankyo UK, Limited: ENHERTU - (TRASTUZUMAB DERUXTECAN) NOW AVAILABLE VIA THE CANCER DRUGS FUND FOR THE TREATMENT OF HER2 POSITIVE METASTATIC BREAST CANCER Reimbursement decisions in Scotland, Wales, and Northern Ireland to be announced later this year Daiichi Sankyo UK, Limited (hereafter, Daiichi Sankyo) and AstraZeneca UK today welcome the news that the National Institute for Health and Care Excellence (NICE) has recommended Enhertu (trastuzumab deruxtecan) for use within the Cancer Drugs Fund (CDF) as an option for treating HER2 positive unresectable or metastatic breast cancer in...
Source: finanznachrichten.de
ENHERTU® ▼ (TRASTUZUMAB DERUXTECAN) NOW AVAILABLE VIA THE CANCER DRUGS FUND FOR THE TREATMENT OF HER2 POSITIVE METASTATIC BREAST CANCER
Press release content from Business Wire. The AP news staff was not involved in its creation. ENHERTU® ▼ (TRASTUZUMAB DERUXTECAN) NOW AVAILABLE VIA THE CANCER DRUGS FUND FOR THE TREATMENT OF HER2 POSITIVE METASTATIC BREAST CANCER April 20, 2021 GMT Daiichi Sankyo UK, Limited (hereafter, Daiichi Sankyo) and AstraZeneca UK today welcome the news that the National Institute for Health and Care Excellence (NICE) has recommended Enhertu ® (trastuzumab deruxtecan) for use within the Cancer Drugs Fund (CDF) as an option for treating HER2 positive unresectable or metastatic breast cancer in adu...
Source: apnews.com